Procalcitonin-guided antibiotic therapy for chronic obstructive pulmonary disease exacerbations

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 6, 2011, Pages 727-735

  Tokman, Sofya ^a   Schuetz, Philipp ^b   Bent, Stephen ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antibiotic guidance; chronic obstructive pulmonary disease; COPD exacerbation; procalcitonin

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; C REACTIVE PROTEIN; NATRIURETIC FACTOR; PLACEBO; PROADRENOMEDULLIN; PROCALCITONIN; STEROID;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE INFECTION; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; DISEASE EXACERBATION; DRUG EXPOSURE; DRUG USE; GRAM NEGATIVE BACTERIUM; HEALTH CARE COST; HOSPITAL READMISSION; HUMAN; MULTIDRUG RESISTANCE; PRESCRIPTION; PREVALENCE; PROCALCITONIN GUIDED ANTIBIOTIC THERAPY; PROGNOSIS; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPUTUM CULTURE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; CALCITONIN; CLOSTRIDIUM DIFFICILE; DISEASE PROGRESSION; DRUG RESISTANCE, BACTERIAL; HUMANS; LUNG; PROTEIN PRECURSORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

EID: 79959707999     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.45     Document Type: Review

References (29)

1. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur. Respir. J. 28(3), 523-532 (2006 (Pubitemid 44794666)
2. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. Respir. Care 47(10), 1184-1199 (2002
3. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 106(2), 196-204 (1987 (Pubitemid 17009877)
4. Ram FS, Rodriguez-Roisin R, Granados- Navarrete A, Garcia-Aymerich J, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. (2), CD004403 (2006
5. Rothberg MB, Pekow PS, Lahti M, Brody O, Skiest DJ, Lindenauer PK. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA 303(20), 2035-2042 (2010
6. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 347(7), 465-471 (2002 (Pubitemid 34879333)
7. Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin. Microbiol. Rev. 14(2), 336-363 (2001 (Pubitemid 32294674)
8. Stolz D, Tamm M. Discriminate use of antibiotics for exacerbation of COPD. Curr. Opin. Pulm. Med. 15(2), 126-132 (2009
9. Kruger S, Ewig S, Papassotiriou J et al. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir. Res. 10, 65 (2009
10. Dandona P, Nix D, Wilson MF et al. Procalcitonin increase after endotoxin injection in normal subjects. J. Clin. Endocrinol. Metab. 79(6), 1605-1608 (1994
11. Linscheid P. In vitro and in vivo calcitonin I gene expression i parenchymal cells: a novel product of human adipose tissue. Endocrinology 144(12), 5578-5584 (2003 (Pubitemid 37476087)
12. Kristoffersen KB, Sogaard OS, Wejse C et al. Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission - a randomized trial. Clin. Microbiol. Infect. 15(5), 481-487 (2009
13. Muller B, Peri G, Doni A et al. High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J. Leukoc. Biol. 72(4), 643-649 (2002 (Pubitemid 36277834)
14. Schuetz P, Albrich W, Christ-Crain M, Chastre J, Mueller B. Procalcitonin for guidance of antibiotic therapy. Expert Rev. Anti Infect. Ther. 8(5), 575-587 (2010
15. Christ-Crain M, Jaccard-Stolz D, Bingisser R et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 363(9409), 600-607 (2004 (Pubitemid 38264177)
16. Schuetz P, Christ-Crain M, Thomann R et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 302(10), 1059-1066 (2009
17. Stolz D, Christ-Crain M, Bingisser R et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 131(1), 9-19 (2007). (Pubitemid 46122969)
18. Schuetz P, Christ-Crain M, Wolbers M et al. Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. BMC Health Serv. Res. 7, 102 (2007
19. Briel M, Schuetz P, Mueller B et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch. Intern. Med. 168(18), 2000-2007; discussion 2007-2008 (2008
20. Lilley R, Feyer AM, Langley J, Wren J. The New Zealand child work-related fatal injury study: 1985-1998. NZ Med. J. 117(1194), U891 (2004
21. Montero M, Dominguez M, Orozco-Levi M, Salvado M, Knobel H. Mortality of COPD patients infected with multi-resistant Pseudomonas aeruginosa: a case and control study. Infection 37(1), 16-19 (2009
22. Christ-Crain M, Stolz D, Bingisser R et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am. Journal Respir. Crit. Care Med. 174(1), 84-93 (2006 (Pubitemid 43955248)
23. Muller F, Christ-Crain M, Bregenzer T et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest 138(1), 121-129 (2010
24. Roberts RR, Hota B, Ahmad I et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin. Infect. Dis. 49(8), 1175-1184 (2009
25. Antonescu-Turcu AL, Tomic R. C-reactive protein and copeptin: prognostic predictors in chronic obstructive pulmonary disease exacerbations. Curr. Opin. Pulm. Med, 15(2), 120-125 (2009
26. Patel AR, Hurst JR, Wedzicha JA. The potential value of biomarkers in diagnosis and staging of COPD and exacerbations. Semin. Respir. Crit. Care Med, 31(3), 267-275 (2010
27. Bernasconi M, Tamm M, Bingisser R et al. Midregional pro-atrial natriuretic peptide predicts survival in exacerbations of COPD. Chest DOI: 10.1378/chest.10-1353 (2010) (Epub ahead of print
28. Schuetz P, Wolbers M, Christ-Crain M et al. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit. Care 14(3), R106 (2010
29. Rammaert B, Verdier N, Cavestri B, Nseir S. Procalcitonin as a prognostic factor in severe acute exacerbation of chronic obstructive pulmonary disease. Respirology 14(7), 969-974 (2009